Goldman Sachs Ups Schering-Plough to In-Line

Analyst James Kelly notes that prescriptions for cholesterol treatments were strong in early 2006

Goldman Sachs upgraded Schering-Plough (SGP) to in-line from underperform, citing factors such as the healthcare company's business making drugs to treat cholesterol.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.